Sangamo Therapeutics(SGMO)

超过5%股东持股披露「修订」

Sangamo Therapeutics(SGMO)02-13 08:15

$Sangamo Therapeutics(SGMO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001193125-24-032402  Act: 34  Size: 41 KB 网页链接查看全文

持股变动声明

Sangamo Therapeutics(SGMO)02-28 06:15

$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-005549  Size: 9 KB 网页链接查看全文

超过5%股东持股披露「修订」

Sangamo Therapeutics(SGMO)04-06 04:05

$Sangamo Therapeutics(SGMO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000814133-24-000068  Act: 34  Size: 4 KB 网页链接查看全文

其他

Sangamo Therapeutics(SGMO)04-20 04:25

$Sangamo Therapeutics(SGMO)$ ARS Annual Report to Security Holders Accession Number: 0001193125-24-102893  Act: 34  Size: 17 MB 网页链接查看全文

持股变动声明

Sangamo Therapeutics(SGMO)02-28 06:15

$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-005550  Size: 9 KB 网页链接查看全文

持股变动声明

Sangamo Therapeutics(SGMO)02-28 06:15

$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-005548  Size: 9 KB 网页链接查看全文

当期报告

Sangamo Therapeutics(SGMO)02-07 05:45

$Sangamo Therapeutics(SGMO)$ 8-K Current report, item 8.01 Accession Number: 0001628280-24-003506  Act: 34  Size: 5 MB 网页链接查看全文

其他

Sangamo Therapeutics(SGMO)04-04 05:25

$Sangamo Therapeutics(SGMO)$ PRE 14A Other preliminary proxy statements Accession Number: 0001628280-24-014660  Act: 34  Size: 17 MB 网页链接查看全文

超过5%股东持股披露「修订」

Sangamo Therapeutics(SGMO)02-10 01:25

$Sangamo Therapeutics(SGMO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000814133-24-000014  Act: 34  Size: 4 KB 网页链接查看全文

年度财报

Sangamo Therapeutics(SGMO)03-13 19:55

$Sangamo Therapeutics(SGMO)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001628280-24-010788  Act: 34  Size: 42 MB 网页链接查看全文

Gin_Eos2019-07-10 00:04

$Sangamo Therapeutics(SGMO)$ 九块多的成本，昨晚十三块多清仓换成了Moderna，看看这次的操作结果～查看全文

用户48783635432019-07-09 10:43

【辉瑞和Sangamo治疗A型血友病基因疗法试验结果良好，缩小与BioMarin差距】辉瑞$辉瑞(PFE)$ 及其合作伙伴Sangamo$Sangamo Therapeutics(SGMO)$ 开发的基因疗法SB-525早期试验结果显示，10名患者接受4种不同剂量的SB-525治疗，剂量越高，体内产生的凝血蛋白就越多，两名患者接受治疗6个月后甚至达到...查看全文

Zuluzulu2019-07-06 14:11

Sangamo backs up early success for hemophilia gene therapy
By Andrew Dunn
Published July 5, 2019
网页链接
$Sangamo Therapeutics(SGMO)$查看全文

Zuluzulu2019-05-23 19:42

May 22, 2019
Biomarin hopes long-term valrox data can stem the bleeding
网页链接
$拜玛林制药(BMRN)$ $Sangamo Therapeutics(SGMO)$查看全文

Zuluzulu2019-05-20 13:26

Sangamo掌控ZFN基因编辑专利十余年，B型血友病临床试验迎来首位患者，全球ZFN临床进展如何
陈婉仪 基因药物 今天
网页链接
$Sangamo Therapeutics(SGMO)$查看全文

Zuluzulu2019-04-04 18:08

Does Sangamo Have the Best Gene Therapy Program Now?
The grandaddy of gene-editing stocks recently provided an encouraging update, but it isn't the only experimental hemophilia therapy out there.
Cory Renauer (TMFang4apples)
Apr 3, 2019 at 8:13AM
网页链接查看全文

Zuluzulu2019-04-02 19:34

Sangamo Provides Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data
‒ Conference call and webcast scheduled for 8:00 a.m. Eastern Time today
网页链接查看全文

Zuluzulu2019-04-02 19:27

Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy
April 2, 2019 at 7:00 AM EDT
网页链接
$Sangamo Therapeutics(SG...查看全文

Zuluzulu2019-03-29 19:27

Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression With Gene Regulation Technology
March 29, 2019 at 7:00 AM EDT
网页链接查看全文

Zuluzulu2019-03-08 18:27

Sangamo Therapeutics Announces Publication Of Data Demonstrating New Zinc Finger Nuclease Architectures Enabling High-Precision Genome Editing
网页链接查看全文

上行空间均超50%，RBC力荐这三只潜力股

智通财经APP获悉，近期，RBC针对Verrica Pharmaceuticals(VRCA.US)、Sangamo Therapeutics(SGMO.US)、GooseHead Insurance(GSHD.US)三家公司发表研报，并强调了这三只股票未来强劲的长期增长前景，预计在未来一年的上行空间将至少达到50... 网页链接

其他

$Sangamo Therapeutics(SGMO)$ ARS Annual Report to Security Holders Accession Number: 0001193125-24-102893  Act: 34  Size: 17 MB 网页链接

股东委托书协议

$Sangamo Therapeutics(SGMO)$ DEF 14A Other definitive proxy statements Accession Number: 0001628280-24-016932  Act: 34  Size: 17 MB 网页链接

超过5%股东持股披露「修订」

$Sangamo Therapeutics(SGMO)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000814133-24-000068  Act: 34  Size: 4 KB 网页链接

其他

$Sangamo Therapeutics(SGMO)$ PRE 14A Other preliminary proxy statements Accession Number: 0001628280-24-014660  Act: 34  Size: 17 MB 网页链接

当期报告

$Sangamo Therapeutics(SGMO)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001193125-24-076613  Act: 34  Size: 915 KB 网页链接

招股说明书

$Sangamo Therapeutics(SGMO)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001193125-24-076462  Act: 33  Size: 3 MB 网页链接

当期报告

$Sangamo Therapeutics(SGMO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001628280-24-010790  Act: 34  Size: 360 KB 网页链接

年度财报

$Sangamo Therapeutics(SGMO)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001628280-24-010788  Act: 34  Size: 42 MB 网页链接

持股变动声明

$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-005552  Size: 9 KB 网页链接

持股变动声明

$Sangamo Therapeutics(SGMO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-005546  Size: 9 KB 网页链接